Israel Active

Israel’s OCON Healthcare (OCON Therapeutics) has been awarded $13 million of orders for its Intra Uterine Ball (IUB) proprietary platform. The purchasers are South America's DKT and UK’s Consilient Healthcare, where the product will be fully reimbursed by the National Health Service.

“Maya” is the Israeli-developed 3D-printed nanotech sticker (reported previously) that adds Covid-19 protection to surgical masks. It now will be mass produced at the DYKAM printing plant in Kibbutz Ein Harod and soon will be available to medical staff in Israel, Canada, Japan, Spain and elsewhere.

Three of the first critical Covid-19 patients treated with the new IgG plasma-derived “passive vaccine” product developed by Israel’s Kamada and Hadassah Medical Center (reported previously), have made a rapid recovery and have now been discharged from Hadassah hospital.

Israeli healthcare provider Clalit, with 4.6 million Israeli members, has authorized the use of the PulseNmore home ultrasound device for expectant mothers. It will reduce numbers of unnecessary hospital visits (average two per pregnancy) during the Covid-19 pandemic.

Israel’s Zebra Medical Vision (reported previously) has partnered with American radiology system distributor, Canon Medical Systems USA (part of the Canon empire). Zebra’s disease analysis platform will be made available to many more locations across the United States.

The vital signs monitoring tool from Israel’s Binah.ai (reported previously) is to be used by 4 Japanese companies. NTT Data - Health Data Bank; Alm’s MySOS - emergencies & new Covid-19 cases; Macnica Networks – monitoring Covid-19 re-infections; SOMPO – insurance policyholder checkups.

Kibbutz Hatzerim is famous for founding drip-irrigation innovator Netafim. It has now co-founded Picodya - developer of the B-Matrix in vitro diagnostics (IVD) platform. B-Matrix gives 15-30min test results for cancer, cardiac dysfunction and viruses (including Covid).

Israel-headquartered Lumenis (reported previously) has launched a superior version 2.0 of its Moses platform for minimal and non-invasive laser removal of urinary (bladder) stones and other stones.

Tel Aviv University researchers reduced secondary cancer following colorectal tumor removal. Deralin and Etopan were given before and after surgery. 3 years later the cancer had spread significantly less than in a control group. Now pancreatic cancer patients will be tested. (latest trial) (2017 trial on breast cancer patients)

Israel’s KAHR Medical has received US FDA approval to begin Phase 1 & 2 clinical (human) trials of its DSP107 treatment of advanced solid tumors (reported previously). The trials will assess DSP107 both by itself and in combination with Roche’s atezolizumab.